Study Of Generation Of Dendritic Cells Derived From Human Cord Mononuclear Cells And The Capacity Of Initiating T Cell-dependent Anti Neuroblastoma Tumor Immune Responses

Objective Dendritic cells(DC) are bone marrow-derived cells that specialize in the uptake, processing, and presentation of foreign and self-antigens.It has been indicated by foreign study groups that reimport of DC pulsed with tumor associated antigen can induce an invigorating specific anti-tumor response in clinic.However ,it is still difficult to obtain adequate DC with simpleness and convenience in vitro. The present study probed into the possibility of obtaining DC from human cord blood mononuclear cells and tested for the capacity of initiating T cell-dependent anti neuroblastoma tumor immune responses by methylthiazoletrazolium(MTT) kit.Methods Human cord blood mononuclearcell were isolated from human cord blood by density gradient centrifugation using lymphocyte separating medium and cord blood mononuclear cells were obtained by adherence and cultured in a liquid culture system with GM-CSF and IL-4 for 15 days.Then the cells were analyzed for phenotypes of CDla by indirect immunofluorescence.DC were tested for the capacity of initiating T cell-dependent anti neuroblastoma tumor immune responses by methylthiazoletrazolium(MTT) kit.Results In the presence of GM-CSF and IL-4,the cells with typical morphological properties of DC at the 15th day were observed .At that time,(43.12±5.83)% CD1a cells were obtained.In addition to these phenotypic properties,the DC of experimental groups could remarkably initiate T cell-dependent anti neuroblastoma tumor immune responses with different ratios compared with control groups ( P<0.01),there were no different lethal effect between 100:1 and 50:1 group( P>0.05), lethal effect of DC was higher in 20:1 group than 100:1 or 50:1 group( P<0.05).Conclusions Human cord blood mononuclear cells could be served as a better source of DC,which can promote the capacity of initiating T cell-dependent anti neuroblastoma tumor immune responses.